Aim: The aim of this study is to develop a new stability indicating reversed-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of Tegafur (TEG) and Uracil (URA) in capsule dosage form. Materials and Methods: Chromatography was carried out on a C18 Phenomenex column (250 mm × 4.6 mm i.d., 5 μm particle size) with an isocratic mobile phase composed of acetate buffer (pH 4) and methanol in the proportion of 70:30 (v/v). The compounds were eluted at a steady flow rate of 1.0 mL/min with a total run time of 10 min. The detection was carried out by ultraviolet-detector at 280 nm. The developed method was validated as per the ICH guidelines, and stability studies were performed. Results and Discussion: TEG retention time was about 5.2 min, and URA was 2.9 min. A calibration curve was obtained in the range of 25-125 μg/mL for TEG and 20-100 μg/mL for URA. Specificity experiments revealed the absence of interference from excipients. The mean assay for TEG was found to be 101.4% (w/w) and for URA was 102.8% (w/w). The method was also evaluated for robustness and ruggedness, and the results obtained were satisfactory. Forced degradation studies were performed for TEG and URA in acidic and alkaline, thermal, and oxidative conditions, and no substantial degradation was observed in all the conditions. Conclusion: It is concluded that the developed stability indicating RP-HPLC method was specific, precise, accurate, sensitive, and robust for the simultaneous estimation of TEG and URA in capsules.
INTRODUCTION
T egafur (TEG) [ Figure 1 ], a prodrug to fluorouracil, is used in combination with uracil (URA) [ Figure 2 ] for the treatment of malignant growth of colon, stomach cancer, bowel cancer, and several other precancerous and cancerous growth conditions. [1] TEG is known to be a potential thymidylate synthase inhibitor. The URA causes higher amounts of 5-Fluorouracil to stay inside the cells and kill them. An extensive literature review revealed that no stability indicating analytical method was reported for the simultaneous estimation of TEG and URA. However, analytical methods for individual drugs and the selected drugs with other drug combinations were reported. Most of the reported methods were pharmacokinetic and bioanalytical methods which were employed in clinical ORIGINAL ARTICLE trials of drug discovery. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Thus, there is a scope for the development of a new stability indicating analytical method for the simultaneous estimation of TEG and URA and validate the developed method as per ICH guidelines. Forced degradation studies were carried to study the effect of various environments on the stability of the drugs.
MATERIALS AND METHODS

Chemicals and reagents
TEG and URA were purchased from TCI Chemicals Pvt. Ltd., Japan. TEG and URA capsules were available in the market as LUPORAL Capsules (LUPIN Ltd., India). All other AR grade chemicals and high-performance liquid chromatography (HPLC) grade solvents were purchased from Merck Pvt. Ltd., Mumbai.
Equipment
The chromatography was performed on Shimadzu Prominence LC system with LC-20AT pump, rheodyne injector, and SPD-20A ultraviolet (UV)-visible detector. The data handling system used was Lab solutions. Calibrated analytical balance (Shimadzu-AY220) and pH meter (Digisun) was also used in the study.
Chromatographic separation conditions
Chromatography was carried out on a C18 Phenomenex column (250 mm × 4.6 mm i.d., 5 μm particle size) with an isocratic mobile phase composed of acetate buffer (pH 4) and methanol in the proportion of 70:30 (v/v), with a steady flow rate of 1.0 mL/min with a run time of 10 min. The detection was carried out by UV-detector at 280 nm. The temperature conditions were maintained at ambient conditions.
Preparation of stock solutions of TEG and URA
Stock solutions of TEG and URA were prepared by transferring 25 mg individually into 25 mL of volumetric flasks and dissolving in 0.1N sodium hydroxide. Finally, volume was made up to the mark with 0.1 N sodium hydroxide to give a solution containing 1000 μg/mL.
Method validation
For linearity, the concentration range 25-125 μg/mL was established for TEG and the concentration range 20-100 μg/ mL was established for URA. 20 μL of each of the prepared stock solutions was injected into the chromatographic system connected to a column, and the average peak area in each of the cases was noted. By plotting concentrations on X-axis and corresponding peak area on Y-axis, the linearity was determined. The precision of the method was demonstrated through two parameters which are injection reproducibility (system precision) and the method precision. Accuracy was performed in three levels of concentration, i.e. 50%, 100%, and 150% of label claim by standard addition technique. The robustness of a method is evaluated by varying method parameters such as flow rate (±0.2 mL/min), wavelength (±2 nm), analyst-to-analyst variation, and determining the effect (if any) on the results of the method.
Assay of capsule dosage form
20 capsules were taken and accurately weighed 0.174 g of fine powder of capsule and transferred into a 50 mL clean, dry volumetric flask, then add 0.1 N sodium hydroxide and kept for sonication for 10 min to dissolve, and then make up the volume with diluent and then filtered through 0.45 μ membrane filter. The test solution was prepared to get a final concentration of 25 μg/mL (TEG) and 56 μg/mL (URA). Triplicate solutions of prepared solutions of 20 μL were injected into the reversed-phase HPLC (RP-HPLC) system, and the chromatographic parameters were analyzed. 
Forced degradation studies
Forced degradation studies were performed for TEG and URA in acidic hydrolysis, basic hydrolysis, thermal, and oxidative conditions. Hydrolysis under acidic conditions was performed by exposing the drug solution to 0.1N HCl at 60°C for 6 h and then cooled, neutralized with 0.1 N NaOH, and the volume was made up to 10 mL with diluent and filtered. Hydrolysis under alkaline conditions was performed by exposing the drug solution to 0.1N NaOH at 60°C for 6 h and then cooled, neutralized with 0.1 N HCl, and the volume was made up to 10 mL with diluent and filtered. Thermal degradation was carried by exposing the drug solution to 60°C for 24 h and then cooled, and volume was made up to 10 mL with diluent and filtered. Oxidative stress was studied by exposing the drug solution to 0.3% v/v H 2 O 2 for 
RESULTS AND DISCUSSION
RP-HPLC method development and optimization
The initial conditions for the chromatography were designed based on the nature of sample, literature, availability, and cost parameters. Several trials were performed by altering mobile phase and keeping the column, flow rate, and other conditions without changing. The result chromatograms [ Figure 3 ] of the trials are presented in Table 1 . The final optimized conditions for the separation were optimized, and the conditions are shown in Table 2 .
A simple RP-HPLC method was developed for the simultaneous estimation of TEG and URA using a C18 phenomenex column (250 mm × 4.6 mm i.d., 5 μm particle size) with an isocratic mobile phase composed of acetate buffer (pH 4) and methanol in the proportion of 70:30 (v/v) with a steady flow rate of 1.0 mL/min with a run time of 10 min. The detection was carried out by UV-detector at 280 nm. TEG retention time was about 5.2 min and URA was 2.9 min which was confirmed by injecting individual drug solutions under the same conditions.
Method validation
The developed method was validated as per the ICH guidelines [16, 17] for various parameters such as linearity, range, precision, accuracy, and robustness [ Figure 4 ]. A calibration curve [ Tables 3 and 4 ] was obtained in the range of 25-125 μg/mL for TEG and 20-100 μg/mL for URA [ Figures 5  and 6 ]. Both calibration curves showed a good correlation of >0.999. Specificity experiments revealed the absence of interference from excipients. The precision was done for Table 5 ] and method [ Table 6 ] precision. All the results were acceptable with % relative standard deviation values <2. Accuracy was performed based on percentage recovery studies [ Table 7 ]. TEG showed a mean percentage recovery of 99.69% and URA showed mean percentage recovery of 100.82%. The method was also evaluated for robustness and ruggedness, and the results obtained were satisfactory [ Figure 7 ].
ASSAY RESULTS
The mean assay for TEG was found to be 101.41% (w/w) and for URA was 102.82% (w/w) [ Table 8 ].
Forced degradation studies
Forced degradation studies were performed for TEG and URA at various conditions such as acidic hydrolysis and basic hydrolysis, thermal, and oxidative conditions, and the percentage degradation values were calculated. All the chromatograms showed no considerable degradation of the drugs at various stress conditions.
CONCLUSIONS
The developed stability indicating RP-HPLC method was specific, precise, accurate, sensitive, and robust for the simultaneous estimation of TEG and URA in capsules. The proposed method can be used for the simultaneous analysis of the two drugs by various pharmaceutical laboratories and research institutions. 
